2013•Shiyong yixue zazhiRequires access

Effects of sequential and combination chemotherapy with docetaxel,epirubicin and cyclophosphamide on fasting plasma glucose of patients with breast cancer

Zhao Ku

Open publisher page 0 citations

Abstract

Objective To compare the effects of docetaxel combined with doxorubicin and cyclophosphamide(TEC) versus doxorubicin and cyclophosphamide followed by docetaxel(EC-T) chemotherapy regimens on fasting plasma glucose in patients with breast cancer.Methods Fasting plasma glucose of 114 women received TEC chemotherapy and 99 women received EC-T chemotherapy in 2007-2010 were retrospectively reviewed and compared.Results Fasting plasma glucose was abnormally increased in 4 patients receiving EC-T chemotherapy regimen and in 12 patients receiving TEC chemotherapy regimen(P 0.05).Conclusion The effects of TEC chemotherapy regimen on fasting plasma glucose were larger than those of EC-T chemotherapy regimen.We suggest that breast cancer patients should choose EC-T chemotherapy regimen in order to decrease the risk of increasing fasting plasma glucose abnormally if permitted.

About this research paper

What this paper is about

Objective To compare the effects of docetaxel combined with doxorubicin and cyclophosphamide(TEC) versus doxorubicin and cyclophosphamide followed by docetaxel(EC-T) chemotherapy regimens on fasting plasma glucose in patients with breast cancer.Methods Fasting plasma glucose of 114 women received TEC chemotherapy and 99 women received EC-T chemotherapy in 2007-2010 were retrospectively reviewed and compared.Results Fasting plasma glucose was abnormally increased in 4 patients receiving EC-T chemotherapy regimen and in 12 patients receiving TEC chemotherapy regimen(P 0.05).Conclusion The effects of TEC chemotherapy regimen on fasting plasma glucose were larger than those of EC-T chemotherapy regimen.We suggest that breast cancer patients should choose EC-T chemotherapy regimen in order to decrease the risk of increasing fasting plasma glucose abnormally if permitted.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To compare the effects of docetaxel combined with doxorubicin and cyclophosphamide(TEC) versus doxorubicin and cyclophosphamide followed by docetaxel(EC-T) chemotherapy regimens on fasting plasma glucose in patients with breast cancer.Methods Fasting plasma glucose of 114 women received TEC chemotherapy and 99 women received EC-T chemotherapy in 2007-2010 were retrospectively reviewed and compared.Results Fasting plasma glucose was abnormally increased in 4 patients receiving EC-T chemotherapy regimen and in 12 patients receiving TEC chemotherapy regimen(P 0.05).Conclusion The effects of TEC chemotherapy regimen on fasting plasma glucose were larger than those of EC-T chemotherapy regimen.We suggest that breast cancer patients should choose EC-T chemotherapy regimen in order to decrease the risk of increasing fasting plasma glucose abnormally if permitted.

Key concepts: Epirubicin, Docetaxel, Chemotherapy, Regimen, Medicine, Cyclophosphamide, Internal medicine, Breast cancer

Back to paper searchBrowse research topicsOriginal source
Effects of sequential and combination chemotherapy with docetaxel,epirubicin and cyclophosphamide on fasting plasma glucose of patients with breast cancer — Research Paper | ScholarLens